Ginkgo para Deterioro cognitivo y pérdida de memoria (ej. Alzheimer)

Ginkgo biloba — 6 estudios científicos revisados

Moderate

¿Sirve Ginkgo para deterioro cognitivo y pérdida de memoria (ej. alzheimer)?

El extracto puede mejorar el flujo sanguíneo cerebral y posee efectos antioxidantes y neuroprotectores que ayudan a mitigar el daño celular en la insuficiencia cerebral.

Compuestos activos involucrados: Alcaloides, Flavonoides, Saponinas, Terpenos

Evidencia Científica

Los siguientes estudios han investigado la relación entre Ginkgo y deterioro cognitivo y pérdida de memoria (ej. alzheimer):

Ginkgo biloba: indications, mechanisms, and safety.

Ginkgo biloba special extract (EGb761) is used in most randomized control trials. Indications include cognition and memory in Alzheimer disease, age-associated dementia, cerebral insufficiency, intermittent claudication, schizophrenia, and multi-infarct dementia. Dosages range from 80 to 720 mg/d for durations of 2 weeks to 2 years. Mechanisms of action include increasing cerebral blood flow, antioxidant and antiinflammatory effects, with antiplatelet effects attributed to flavone and terpene lactones. Possible interactions with monoamine oxidase inhibitors, alprazolam, haloperidol, warfarin,

PubMed: 23538078

Ginkgo biloba.

Ginkgo biloba is commonly used in the treatment of early-stage Alzheimer's disease, vascular dementia, peripheral claudication, and tinnitus of vascular origin. Multiple trials investigating the efficacy of ginkgo for treating cerebrovascular disease and dementia have been performed, and systematic reviews suggest the herb can improve the symptoms of dementia. Ginkgo is generally well tolerated, but it can increase the risk of bleeding if used in combination with warfarin, antiplatelet agents, and certain other herbal medications. Clinical issues of safety, dosing, use in the perioperative per

PubMed: 13678141

The pathogenesis of Alzheimer's disease (AD), a degenerative disease of the central nervous system, remains unclear. The main manifestations of AD include cognitive and behavioral disorders, neuropsychiatric symptoms, neuroinflammation, amyloid plaques, and neurofibrillary tangles. However, current drugs for AD once the dementia stage has been reached only treat symptoms and do not delay progression, and the research and development of targeted drugs for AD have reached a bottleneck. Thus, other treatment options are needed. Bioactive ingredients derived from plants are promising therapeutic a

PubMed: 38654507

Ginkgo biloba flavonoids: Analysis of functions, regulatory mechanisms, and extraction.

Ginkgo biloba L. is a protected relict species of the genus Ginkgo in the Ginkgoaceae family that is valued for its ornamental, economic, and medicinal properties. Flavonoids, the primary medicinal components in G. biloba, have anti-inflammatory, anticancer, and antioxidant effects. They specifically inhibit xanthine oxidase and platelet-activating factor receptors, making them effective in treating Alzheimer's disease and hypertension.

PubMed: 40462387

Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease.

Extracts made from plants are complex mixtures of substances with varying compositions depending on the plant material and method of manufacture. This complexity makes it difficult for scientists and clinicians to interpret findings from pharmacological and clinical research. We performed a narrative review summarizing information on ginkgo biloba leaf extract, its composition, pharmacological data and clinical evidence supporting its administration for the treatment of Alzheimer's disease (AD). Medicinal products containing ginkgo biloba leaf extract which are manufactured in compliance with

PubMed: 39422946

Seguridad y Precauciones

El uso de Ginkgo biloba requiere una vigilancia clínica rigurosa debido a su compleja farmacología. En el caso del embarazo y la lactancia, no existe evidencia suficiente que garantice la seguridad del uso de extractos de Ginkgo en mujeres gestantes o lactantes; por lo tanto, se recomienda evitar su consumo para prevenir posibles riesgos al desarrollo fetal o neonatal no cuantificados. En cuanto a la población pediátrica, el uso en niños menores de 12 años no está establecido ni se recomienda debido a la falta de estudios de seguridad a largo plazo en organismos en desarrollo. Un riesgo crítico reside en las interacciones medicamentosas. El Ginkgo posee efectos antiplaquetarios (debido a sus lactonas terpénicas y flavonoides) que pueden potenciar peligrosamente el efecto de la warfarina y otros anticoagulantes, aumentando el riesgo de hemorragias espontáneas. Asimismo, se han reportado interacciones con fármacos como el alprazolam y el haloperidol, lo que podría alterar el estado neurológico.

Ver perfil de seguridad completo de Ginkgo →

Perfil completo: Ver todos los usos y evidencia de Ginkgo →